Abstract: Background: Hepatitis C virus is a frequent cause of hepatocellular carcinoma. Sofosbuvir is an HCV NS5B nucleotide polymerase inhibitor with similar in vitro activity against HCV genotypes that have been evaluated extensively in phase II and III interferon-free clinical trials. Hepatitis C (HCV) infects more than 185 million individuals worldwide. Twenty percent of patients chronically infected with HCV progress to cirrhosis. The aims of this study were to compare the safety and efficacy of Sofosbuvir for the initial treatment of chronic hepatitis C. Materials and Methods: A literature search of PubMed, Wiley online library, Scopus, Google Scholar, and Web of Science was conducted from 2015 to 2022 using the keywords, Sofosbuvir and Hepatitis C. The Titles of articles were reviewed, and those who were more patients out of 12 were selected. Results: A total of 89 articles published from 2015-2022 were studied. In 23 of the reviewed articles, the number of patients and results were studied. In total, Sofosbuvir was found to be used in the treatment process of 4650 patients for a total duration of 15 to 30 weeks. The efficiency of the drug was estimated to be 82.1 % on average; it varied for different genotypes of the disease. Conclusion: The study shows that Sofosbuvir can be used as an effective drug for the treatment of Hepatitis C. New, short-duration, simpler therapies result in high SVR rates for HCV-infected patients. This drug is taken in combination with a Ribavirin between 10 to 24 weeks (on average). Keywords
